Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

867296

registered interest
date	20/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Bowel Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	What the timetable is for the implementation of the faecal immunochemical test for bowel cancer screening.
tabling member constituency	Eastbourne
tabling member printed	Stephen Lloyd
uin	904478
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>The UK National Screening Committee has recommended that the faecal immunochemical test (FIT) be the primary screening test for bowel cancer and NHS England remains absolutely committed to implementing FIT in 2018/19.</p><p> </p><p>NHS England is working with Public Health England to finalise a number of practical arrangements around sensitivity, production and distribution of FIT kits, and diagnostic and pathology workforce capacity to ensure that when FIT is implemented, it is sustainable.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/03/2018 17:31:43 answering member 4067 label Biography information for Steve Brine
tabling member	3968 label Biography information for Stephen Lloyd

866427

registered interest
date	19/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care what assessment he has made of the effect of charging VAT on the affordability and accessibility of medicines.
tabling member constituency	Brentford and Isleworth
tabling member printed	Ruth Cadbury
uin	904465
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>Value Added Tax (VAT) paid by the National Health Service on the purchase of medicines is fully incorporated within the funding allocated to the NHS each year.</p><p>As is the case with many other goods and services, VAT is chargeable at 20% to members of the public when purchasing over the counter and non-prescription medicines.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/03/2018 15:37:51 answering member 4067 label Biography information for Steve Brine
tabling member	4389 label Biography information for Ruth Cadbury

864293

registered interest
date	15/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	East Lancashire Clinical Commissioning Group: Salute
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what representations his Department has received on recent work undertaken by East Lancashire Clinical Commissioning Group and the charity Salute.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	132777
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>NHS England has advised that following the hon. Member’s letter to the Chief Executive of NHS England, they have launched an investigation.</p><p> </p><p>They also have advised that they are unable to provide further information until the investigation is concluded.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/03/2018 16:42:20 answering member 4067 label Biography information for Steve Brine
tabling member	1538 label Biography information for Rosie Cooper

864294

registered interest
date	15/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Midlands and Lancashire Commissioning Support Unit
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the validity of Midlands and Lancashire Commissioning Support Unit's policy of allowing themselves up to 40 working days to respond to constituent casework regardless of whether an investigation is needed.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	132778
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>It is important that clinical commissioning groups (CCGs) should respond to constituent casework in a timely manner.</p><p> </p><p>NHS England has advised that the Chief Officer for Lancashire CCG, Mike McQuire, has written to the hon. Member about the role of NHS Midlands and Lancashire Commissioning Support Unit in working with NHS West Lancashire CCG to produce responses to correspondence from hon. Members.</p><p> </p><p>We understand he has set out the process for dealing with letters and the responsibilities of the respective organisations involved in providing accurate responses to hon. Members or constituents, and has requested a further meeting with the hon. Member to discuss the matter further.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/03/2018 16:33:13 answering member 4067 label Biography information for Steve Brine
tabling member	1538 label Biography information for Rosie Cooper

864434

registered interest
date	15/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that GPs receive a copy of Crohn's & Colitis UK's latest Inflammatory Bowel Disease toolkit to improve (a) awareness, (b) early diagnosis and (b) treatment plans for that condition.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	132917
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>In August 2017, Crohn’s and Colitis UK in partnership with the Royal College of General Practitioners (RCGP) launched a new Inflammatory Bowel Disease (IBD) toolkit: an online resource for general practitioners (GPs) and healthcare professionals designed to improve understanding of Crohn’s Disease and Ulcerative Colitis, collectively known as IBD. The Toolkit was developed as part of a 12 month project on IBD, and includes a range of resources for GPs to improve detection of inflammatory bowel disease and to support primary care clinicians in treating, managing and referring patients with the condition.</p><p> </p><p>The Toolkit was promoted at events across the United Kingdom and an IBD Twitter chat with an expert panel was held in February 2018. The Toolkit, regional events and Twitter session were all promoted to GPs via the RCGP website and newsletter and more widely by Crohn’s and Colitis UK. The Toolkit can be found at the following link:</p><p> </p><p><a href="http://www.rcgp.org.uk/clinical-and-research/resources/toolkits/inflammatory-bowel-disease-toolkit.aspx" target="_blank">www.rcgp.org.uk/clinical-and-research/resources/toolkits/inflammatory-bowel-disease-toolkit.aspx</a></p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/03/2018 16:31:16 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn

864441

registered interest
date	15/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate has been made of the number of people with undiagnosed HIV, broken down by NUTS 1 region, in each year since 2013-14.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	132924
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>Estimates of undiagnosed HIV infection are not available by Nomenclature of Territorial Units for Statistics (NUTS) 1 region.</p><p><strong> </strong></p><p>There may be some regional differences in treatment rates or drugs used based on variations in patient demographics or the available drug contracts.</p><p> </p><p>Regional HIV networks determine prescribing guidelines which align with national commissioning policies for antiretroviral therapies. These guidelines are overseen by the HIV Clinical Reference Group – which includes strong patient representation - who provide clinical advice on HIV treatment issues and raise concerns from the community should there be perceived issue around equitable access.</p><p> </p><p>Working closely with Public Health England (PHE), NHS England has produced a clinical dashboard that summarises clinical performance at the trust level. PHE prepares and analyses all the data that feeds into the Clinical Reference Group HIV dashboard. Two dashboard indicators measure anti-retroviral therapy coverage among all people accessing HIV care and among people with a low CD4 count (indicative of immunosuppression). Further information on the dashboard is available here:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/</a></p><p> </p><p> </p><p>Data are not available by NUTS for the proportion of people living with diagnosed HIV infection who are not receiving antiretroviral therapy treatment.</p><p> </p><p>Antiretroviral therapy is now so effective that people receiving treatment can expect to have a near normal life expectancy. Consequently, the proportion of people receiving treatment continues to rise each year since death rates remain low. The higher antiretroviral therapy coverage rate observed in some regions is partially due to the longer history of the epidemic in these areas.</p><p> </p><p> </p><p>British HIV Association guidelines have progressively reduced the threshold at which patients may begin antiretroviral therapy. In 2018, NHS England announced routine commissioning of ‘Immediate Access to Antiretroviral Therapy’ from 1 April 2018.</p><p> </p><p><a href="https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/" target="_blank">https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/</a></p><p> </p><p>This enables all patients to access treatment at the point of diagnosis or at the time the patient wishes to commence treatment. It has also clarified the position on the funding of antiretroviral therapy for immediate treatment among patients newly diagnosed with HIV.</p><p> </p><p>NHS England and PHE keep under review data on the rates of uptake of antiretroviral treatment and will continue to do so to identify any unwarranted variation.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 132925 132926 132927 question first answered 20/03/2018 16:36:27 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

864442

registered interest
date	15/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps (a) his Department, (b) NHS England and (c) Public Health England is taking to ensure the equity of access to antiretoroviral therapy in the regions.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	132925
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>Estimates of undiagnosed HIV infection are not available by Nomenclature of Territorial Units for Statistics (NUTS) 1 region.</p><p><strong> </strong></p><p>There may be some regional differences in treatment rates or drugs used based on variations in patient demographics or the available drug contracts.</p><p> </p><p>Regional HIV networks determine prescribing guidelines which align with national commissioning policies for antiretroviral therapies. These guidelines are overseen by the HIV Clinical Reference Group – which includes strong patient representation - who provide clinical advice on HIV treatment issues and raise concerns from the community should there be perceived issue around equitable access.</p><p> </p><p>Working closely with Public Health England (PHE), NHS England has produced a clinical dashboard that summarises clinical performance at the trust level. PHE prepares and analyses all the data that feeds into the Clinical Reference Group HIV dashboard. Two dashboard indicators measure anti-retroviral therapy coverage among all people accessing HIV care and among people with a low CD4 count (indicative of immunosuppression). Further information on the dashboard is available here:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/</a></p><p> </p><p> </p><p>Data are not available by NUTS for the proportion of people living with diagnosed HIV infection who are not receiving antiretroviral therapy treatment.</p><p> </p><p>Antiretroviral therapy is now so effective that people receiving treatment can expect to have a near normal life expectancy. Consequently, the proportion of people receiving treatment continues to rise each year since death rates remain low. The higher antiretroviral therapy coverage rate observed in some regions is partially due to the longer history of the epidemic in these areas.</p><p> </p><p> </p><p>British HIV Association guidelines have progressively reduced the threshold at which patients may begin antiretroviral therapy. In 2018, NHS England announced routine commissioning of ‘Immediate Access to Antiretroviral Therapy’ from 1 April 2018.</p><p> </p><p><a href="https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/" target="_blank">https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/</a></p><p> </p><p>This enables all patients to access treatment at the point of diagnosis or at the time the patient wishes to commence treatment. It has also clarified the position on the funding of antiretroviral therapy for immediate treatment among patients newly diagnosed with HIV.</p><p> </p><p>NHS England and PHE keep under review data on the rates of uptake of antiretroviral treatment and will continue to do so to identify any unwarranted variation.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 132924 132926 132927 question first answered 20/03/2018 16:36:27 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

864443

registered interest
date	15/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of people diagnosed with HIV infection are not receiving antiretroviral treatment by NUTS 1 region in each year since 2013-14.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	132926
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>Estimates of undiagnosed HIV infection are not available by Nomenclature of Territorial Units for Statistics (NUTS) 1 region.</p><p><strong> </strong></p><p>There may be some regional differences in treatment rates or drugs used based on variations in patient demographics or the available drug contracts.</p><p> </p><p>Regional HIV networks determine prescribing guidelines which align with national commissioning policies for antiretroviral therapies. These guidelines are overseen by the HIV Clinical Reference Group – which includes strong patient representation - who provide clinical advice on HIV treatment issues and raise concerns from the community should there be perceived issue around equitable access.</p><p> </p><p>Working closely with Public Health England (PHE), NHS England has produced a clinical dashboard that summarises clinical performance at the trust level. PHE prepares and analyses all the data that feeds into the Clinical Reference Group HIV dashboard. Two dashboard indicators measure anti-retroviral therapy coverage among all people accessing HIV care and among people with a low CD4 count (indicative of immunosuppression). Further information on the dashboard is available here:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/</a></p><p> </p><p> </p><p>Data are not available by NUTS for the proportion of people living with diagnosed HIV infection who are not receiving antiretroviral therapy treatment.</p><p> </p><p>Antiretroviral therapy is now so effective that people receiving treatment can expect to have a near normal life expectancy. Consequently, the proportion of people receiving treatment continues to rise each year since death rates remain low. The higher antiretroviral therapy coverage rate observed in some regions is partially due to the longer history of the epidemic in these areas.</p><p> </p><p> </p><p>British HIV Association guidelines have progressively reduced the threshold at which patients may begin antiretroviral therapy. In 2018, NHS England announced routine commissioning of ‘Immediate Access to Antiretroviral Therapy’ from 1 April 2018.</p><p> </p><p><a href="https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/" target="_blank">https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/</a></p><p> </p><p>This enables all patients to access treatment at the point of diagnosis or at the time the patient wishes to commence treatment. It has also clarified the position on the funding of antiretroviral therapy for immediate treatment among patients newly diagnosed with HIV.</p><p> </p><p>NHS England and PHE keep under review data on the rates of uptake of antiretroviral treatment and will continue to do so to identify any unwarranted variation.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 132924 132925 132927 question first answered 20/03/2018 16:36:27 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

864444

registered interest
date	15/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the reasons for regional differences in the uptake of antiretroviral therapy.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	132927
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>Estimates of undiagnosed HIV infection are not available by Nomenclature of Territorial Units for Statistics (NUTS) 1 region.</p><p><strong> </strong></p><p>There may be some regional differences in treatment rates or drugs used based on variations in patient demographics or the available drug contracts.</p><p> </p><p>Regional HIV networks determine prescribing guidelines which align with national commissioning policies for antiretroviral therapies. These guidelines are overseen by the HIV Clinical Reference Group – which includes strong patient representation - who provide clinical advice on HIV treatment issues and raise concerns from the community should there be perceived issue around equitable access.</p><p> </p><p>Working closely with Public Health England (PHE), NHS England has produced a clinical dashboard that summarises clinical performance at the trust level. PHE prepares and analyses all the data that feeds into the Clinical Reference Group HIV dashboard. Two dashboard indicators measure anti-retroviral therapy coverage among all people accessing HIV care and among people with a low CD4 count (indicative of immunosuppression). Further information on the dashboard is available here:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/</a></p><p> </p><p> </p><p>Data are not available by NUTS for the proportion of people living with diagnosed HIV infection who are not receiving antiretroviral therapy treatment.</p><p> </p><p>Antiretroviral therapy is now so effective that people receiving treatment can expect to have a near normal life expectancy. Consequently, the proportion of people receiving treatment continues to rise each year since death rates remain low. The higher antiretroviral therapy coverage rate observed in some regions is partially due to the longer history of the epidemic in these areas.</p><p> </p><p> </p><p>British HIV Association guidelines have progressively reduced the threshold at which patients may begin antiretroviral therapy. In 2018, NHS England announced routine commissioning of ‘Immediate Access to Antiretroviral Therapy’ from 1 April 2018.</p><p> </p><p><a href="https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/" target="_blank">https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/</a></p><p> </p><p>This enables all patients to access treatment at the point of diagnosis or at the time the patient wishes to commence treatment. It has also clarified the position on the funding of antiretroviral therapy for immediate treatment among patients newly diagnosed with HIV.</p><p> </p><p>NHS England and PHE keep under review data on the rates of uptake of antiretroviral treatment and will continue to do so to identify any unwarranted variation.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 132924 132925 132926 question first answered 20/03/2018 16:36:27 answering member 4067 label Biography information for Steve Brine
tabling member	1533 label Biography information for Dame Diana Johnson

864464

registered interest
date	15/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Obesity: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is developing a new child obesity plan; and what assessment he has made of the potential merits of developing a new child obesity plan that includes steps to reduce child tooth decay.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	132947
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>Improving the oral health of children is a priority for this Government. Key measures in our world-leading childhood obesity plan include the soft drinks industry levy and sugar reduction and wider reformulation programme which are reducing the amount of sugar children consume.</p><p> </p><p>Current advertising restrictions in the United Kingdom on high fat, salt or sugar (HFSS) products are among the toughest in the world. Strict new rules came into effect in July 2017 banning the advertising of HFSS food or drink products in children’s media. These restrictions apply across all non-broadcast media including in print, cinema, online and in social media.</p><p> </p><p>In August 2017 we announced £5 million investment in a policy research unit on childhood obesity to provide a robust evidence, evaluation and research capability including looking at the impact of marketing (including advertising) on childhood obesity. We will use this, alongside other reports and data published on progress in delivering our plan, to determine whether sufficient progress has been made and whether alternative levers need to be considered.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 132948 question first answered 20/03/2018 16:39:52 answering member 4067 label Biography information for Steve Brine
tabling member	298 label Biography information for Steve McCabe